| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 102 | 2025 | 797 | 19.290 |
Why?
|
| Cystadenocarcinoma, Serous | 11 | 2025 | 68 | 4.210 |
Why?
|
| Tumor Microenvironment | 25 | 2025 | 554 | 3.720 |
Why?
|
| Neoplasm Metastasis | 23 | 2025 | 1061 | 2.550 |
Why?
|
| Adipocytes | 7 | 2023 | 169 | 2.480 |
Why?
|
| Peritoneal Neoplasms | 15 | 2025 | 184 | 2.400 |
Why?
|
| Neoplasms, Glandular and Epithelial | 12 | 2017 | 78 | 2.080 |
Why?
|
| Omentum | 12 | 2025 | 68 | 2.070 |
Why?
|
| Cell Line, Tumor | 49 | 2025 | 2755 | 1.960 |
Why?
|
| Cancer-Associated Fibroblasts | 5 | 2025 | 40 | 1.960 |
Why?
|
| Female | 139 | 2025 | 48708 | 1.870 |
Why?
|
| Adnexal Diseases | 3 | 2025 | 22 | 1.850 |
Why?
|
| Proteomics | 9 | 2025 | 264 | 1.720 |
Why?
|
| Cancer Survivors | 3 | 2023 | 88 | 1.690 |
Why?
|
| Proto-Oncogene Proteins c-met | 11 | 2015 | 199 | 1.570 |
Why?
|
| Gene Expression Regulation, Neoplastic | 25 | 2025 | 1338 | 1.560 |
Why?
|
| Drug Resistance, Neoplasm | 14 | 2024 | 636 | 1.540 |
Why?
|
| Metformin | 8 | 2025 | 125 | 1.500 |
Why?
|
| Humans | 171 | 2025 | 93522 | 1.470 |
Why?
|
| Fallopian Tubes | 6 | 2025 | 48 | 1.430 |
Why?
|
| Epithelial Cells | 14 | 2025 | 700 | 1.380 |
Why?
|
| Mice | 50 | 2025 | 12269 | 1.360 |
Why?
|
| Mice, Nude | 25 | 2020 | 824 | 1.350 |
Why?
|
| Carcinoma, Endometrioid | 6 | 2025 | 59 | 1.330 |
Why?
|
| Neoplasm Invasiveness | 21 | 2025 | 572 | 1.310 |
Why?
|
| Urokinase-Type Plasminogen Activator | 11 | 2015 | 49 | 1.300 |
Why?
|
| MicroRNAs | 11 | 2023 | 580 | 1.270 |
Why?
|
| Antineoplastic Agents | 15 | 2020 | 2303 | 1.250 |
Why?
|
| Endometrial Neoplasms | 6 | 2025 | 227 | 1.220 |
Why?
|
| Animals | 70 | 2025 | 28155 | 1.160 |
Why?
|
| Xenograft Model Antitumor Assays | 14 | 2025 | 526 | 1.140 |
Why?
|
| High-Throughput Screening Assays | 3 | 2019 | 61 | 1.130 |
Why?
|
| Neoplasms | 15 | 2023 | 3169 | 1.110 |
Why?
|
| Cell Transformation, Neoplastic | 6 | 2013 | 457 | 1.110 |
Why?
|
| Fallopian Tube Neoplasms | 4 | 2021 | 39 | 1.100 |
Why?
|
| Nicotinamide N-Methyltransferase | 2 | 2025 | 9 | 1.070 |
Why?
|
| Cytoreduction Surgical Procedures | 5 | 2025 | 92 | 1.040 |
Why?
|
| Cell Proliferation | 19 | 2025 | 1741 | 1.020 |
Why?
|
| Tumor Cells, Cultured | 22 | 2019 | 1028 | 1.000 |
Why?
|
| Fibronectins | 3 | 2014 | 100 | 1.000 |
Why?
|
| Carboplatin | 2 | 2025 | 322 | 0.980 |
Why?
|
| Adipose Tissue | 4 | 2022 | 270 | 0.950 |
Why?
|
| Naphthoquinones | 1 | 2025 | 8 | 0.920 |
Why?
|
| Proteogenomics | 1 | 2025 | 7 | 0.910 |
Why?
|
| 5-Methylcytosine | 2 | 2024 | 121 | 0.900 |
Why?
|
| Aniline Compounds | 1 | 2025 | 62 | 0.890 |
Why?
|
| Cell Adhesion | 16 | 2017 | 416 | 0.880 |
Why?
|
| Ovary | 5 | 2022 | 254 | 0.880 |
Why?
|
| Imidazoles | 2 | 2025 | 138 | 0.880 |
Why?
|
| Disease Progression | 16 | 2025 | 1531 | 0.880 |
Why?
|
| Fibroblasts | 8 | 2015 | 756 | 0.860 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2025 | 100 | 0.860 |
Why?
|
| Models, Biological | 5 | 2015 | 1768 | 0.860 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2025 | 203 | 0.830 |
Why?
|
| Paclitaxel | 3 | 2016 | 479 | 0.820 |
Why?
|
| Gene Expression Profiling | 7 | 2025 | 1518 | 0.810 |
Why?
|
| Glycerol | 1 | 2023 | 34 | 0.790 |
Why?
|
| Sulfonamides | 1 | 2025 | 331 | 0.770 |
Why?
|
| Enzyme Inhibitors | 4 | 2025 | 641 | 0.770 |
Why?
|
| Extracellular Matrix | 4 | 2015 | 256 | 0.750 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2025 | 337 | 0.750 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2024 | 95 | 0.740 |
Why?
|
| Glycogen | 2 | 2019 | 59 | 0.720 |
Why?
|
| Coculture Techniques | 9 | 2020 | 170 | 0.720 |
Why?
|
| Tumor Burden | 6 | 2020 | 321 | 0.720 |
Why?
|
| Neoplasm Grading | 9 | 2025 | 402 | 0.680 |
Why?
|
| Artificial Intelligence | 1 | 2025 | 391 | 0.670 |
Why?
|
| Antineoplastic Protocols | 1 | 2021 | 9 | 0.670 |
Why?
|
| Matrix Metalloproteinase 2 | 6 | 2009 | 48 | 0.670 |
Why?
|
| Signal Transduction | 17 | 2024 | 3502 | 0.670 |
Why?
|
| Cell Movement | 9 | 2019 | 809 | 0.660 |
Why?
|
| Fatty Acid-Binding Proteins | 2 | 2020 | 25 | 0.650 |
Why?
|
| Carcinoma | 4 | 2015 | 439 | 0.650 |
Why?
|
| Mental Health | 2 | 2021 | 188 | 0.640 |
Why?
|
| Neoplastic Stem Cells | 2 | 2024 | 172 | 0.640 |
Why?
|
| Neoadjuvant Therapy | 3 | 2025 | 446 | 0.630 |
Why?
|
| Hyperthermia, Induced | 1 | 2020 | 75 | 0.620 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2025 | 2544 | 0.600 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 10 | 2013 | 20 | 0.600 |
Why?
|
| Epithelium | 8 | 2023 | 316 | 0.600 |
Why?
|
| Receptors, Cell Surface | 8 | 2007 | 292 | 0.600 |
Why?
|
| Pandemics | 3 | 2022 | 873 | 0.580 |
Why?
|
| Genomics | 3 | 2025 | 848 | 0.580 |
Why?
|
| Liposomes | 2 | 2016 | 98 | 0.580 |
Why?
|
| Aged | 34 | 2025 | 20439 | 0.560 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 624 | 0.560 |
Why?
|
| Mutation | 11 | 2025 | 4272 | 0.550 |
Why?
|
| Transgender Persons | 1 | 2020 | 113 | 0.550 |
Why?
|
| CD36 Antigens | 1 | 2018 | 15 | 0.550 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2021 | 1448 | 0.540 |
Why?
|
| Stress, Psychological | 1 | 2021 | 342 | 0.540 |
Why?
|
| Middle Aged | 37 | 2025 | 27580 | 0.530 |
Why?
|
| Depression | 2 | 2021 | 544 | 0.530 |
Why?
|
| Proteome | 4 | 2025 | 153 | 0.530 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2017 | 27 | 0.510 |
Why?
|
| Biomarkers, Tumor | 13 | 2025 | 1660 | 0.510 |
Why?
|
| Integrin alpha5beta1 | 4 | 2011 | 11 | 0.490 |
Why?
|
| Promoter Regions, Genetic | 16 | 2015 | 962 | 0.470 |
Why?
|
| Blotting, Western | 9 | 2015 | 784 | 0.460 |
Why?
|
| Aged, 80 and over | 20 | 2021 | 7063 | 0.460 |
Why?
|
| Integrin alpha5 | 3 | 2013 | 5 | 0.450 |
Why?
|
| Transcription Factor AP-1 | 9 | 2007 | 66 | 0.450 |
Why?
|
| Cadherins | 4 | 2009 | 180 | 0.450 |
Why?
|
| Matrix Metalloproteinase 9 | 8 | 2008 | 83 | 0.430 |
Why?
|
| Sequence Analysis, DNA | 2 | 2016 | 893 | 0.430 |
Why?
|
| Antibodies, Monoclonal | 4 | 2013 | 1395 | 0.410 |
Why?
|
| Disease Models, Animal | 5 | 2013 | 2495 | 0.410 |
Why?
|
| Carcinogenesis | 3 | 2021 | 235 | 0.400 |
Why?
|
| Molecular Targeted Therapy | 3 | 2025 | 304 | 0.400 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 4 | 1997 | 85 | 0.390 |
Why?
|
| Ultrasonography | 3 | 2025 | 702 | 0.390 |
Why?
|
| Transcription Factors | 10 | 2025 | 1691 | 0.390 |
Why?
|
| Adult | 29 | 2025 | 27921 | 0.390 |
Why?
|
| Apoptosis | 7 | 2016 | 1721 | 0.380 |
Why?
|
| Hepatocyte Growth Factor | 6 | 2010 | 86 | 0.380 |
Why?
|
| Mitogen-Activated Protein Kinases | 6 | 2001 | 216 | 0.380 |
Why?
|
| Hypoglycemic Agents | 4 | 2019 | 379 | 0.370 |
Why?
|
| Stromal Cells | 4 | 2019 | 151 | 0.370 |
Why?
|
| Spheroids, Cellular | 2 | 2017 | 31 | 0.370 |
Why?
|
| Anoikis | 2 | 2011 | 7 | 0.360 |
Why?
|
| Extracellular Traps | 2 | 2025 | 16 | 0.360 |
Why?
|
| Transcriptome | 5 | 2025 | 762 | 0.360 |
Why?
|
| Neutrophils | 3 | 2025 | 324 | 0.360 |
Why?
|
| Cell Culture Techniques | 5 | 2017 | 197 | 0.360 |
Why?
|
| Ligands | 4 | 2025 | 476 | 0.350 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2011 | 34 | 0.350 |
Why?
|
| Prognosis | 15 | 2019 | 3912 | 0.340 |
Why?
|
| Salpingectomy | 1 | 2011 | 4 | 0.340 |
Why?
|
| Carboxymethylcellulose Sodium | 1 | 2011 | 8 | 0.340 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2011 | 78 | 0.330 |
Why?
|
| Anilides | 1 | 2011 | 45 | 0.330 |
Why?
|
| Cell Survival | 5 | 2020 | 1004 | 0.330 |
Why?
|
| Cell Communication | 4 | 2018 | 216 | 0.330 |
Why?
|
| Quinolines | 1 | 2011 | 85 | 0.330 |
Why?
|
| Estradiol | 1 | 2011 | 247 | 0.330 |
Why?
|
| Ovariectomy | 1 | 2011 | 91 | 0.330 |
Why?
|
| HIV Infections | 1 | 2020 | 961 | 0.330 |
Why?
|
| Tissue Adhesions | 1 | 2011 | 53 | 0.330 |
Why?
|
| Glucose | 4 | 2023 | 692 | 0.330 |
Why?
|
| Hyaluronic Acid | 1 | 2011 | 53 | 0.330 |
Why?
|
| Immunohistochemistry | 15 | 2020 | 1799 | 0.320 |
Why?
|
| Vitronectin | 2 | 2008 | 4 | 0.320 |
Why?
|
| Drug Synergism | 2 | 2025 | 315 | 0.320 |
Why?
|
| Glycolysis | 4 | 2019 | 187 | 0.320 |
Why?
|
| Receptor, ErbB-2 | 3 | 2008 | 280 | 0.310 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2009 | 16 | 0.310 |
Why?
|
| Contraceptives, Oral, Synthetic | 1 | 2009 | 6 | 0.310 |
Why?
|
| Indoles | 1 | 2011 | 303 | 0.310 |
Why?
|
| Ethinyl Estradiol | 1 | 2009 | 16 | 0.310 |
Why?
|
| Norethindrone | 1 | 2009 | 13 | 0.310 |
Why?
|
| Neoplasm Proteins | 5 | 2020 | 537 | 0.310 |
Why?
|
| Neuropeptides | 3 | 2004 | 114 | 0.300 |
Why?
|
| Gene Expression Regulation, Enzymologic | 4 | 2001 | 216 | 0.300 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2021 | 87 | 0.300 |
Why?
|
| Up-Regulation | 6 | 2020 | 730 | 0.300 |
Why?
|
| RNA, Messenger | 10 | 2018 | 2026 | 0.290 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2009 | 99 | 0.290 |
Why?
|
| Retrospective Studies | 9 | 2025 | 10166 | 0.290 |
Why?
|
| Protein-Tyrosine Kinases | 4 | 2007 | 302 | 0.290 |
Why?
|
| Peritoneum | 3 | 2018 | 52 | 0.290 |
Why?
|
| rac GTP-Binding Proteins | 3 | 2004 | 24 | 0.280 |
Why?
|
| Piperidines | 1 | 2010 | 165 | 0.280 |
Why?
|
| Tissue Culture Techniques | 1 | 2009 | 81 | 0.280 |
Why?
|
| Methylation | 3 | 2025 | 288 | 0.280 |
Why?
|
| Pyridines | 2 | 2010 | 303 | 0.280 |
Why?
|
| Cells, Cultured | 7 | 2019 | 2850 | 0.280 |
Why?
|
| RNA, Small Interfering | 6 | 2019 | 555 | 0.270 |
Why?
|
| Transfection | 7 | 2015 | 880 | 0.270 |
Why?
|
| BRCA1 Protein | 2 | 2021 | 214 | 0.270 |
Why?
|
| Integrin beta1 | 1 | 2007 | 34 | 0.270 |
Why?
|
| Disease-Free Survival | 7 | 2017 | 1170 | 0.270 |
Why?
|
| Thrombin | 1 | 2007 | 60 | 0.270 |
Why?
|
| Homeodomain Proteins | 4 | 2014 | 556 | 0.260 |
Why?
|
| Colonic Neoplasms | 2 | 2025 | 579 | 0.260 |
Why?
|
| Histones | 3 | 2025 | 361 | 0.260 |
Why?
|
| Neoplasm Staging | 9 | 2025 | 2017 | 0.260 |
Why?
|
| Keratins | 4 | 2007 | 62 | 0.250 |
Why?
|
| Adenocarcinoma, Clear Cell | 2 | 2025 | 61 | 0.240 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2019 | 296 | 0.240 |
Why?
|
| Antigens, Neoplasm | 2 | 2018 | 355 | 0.240 |
Why?
|
| Single-Cell Analysis | 3 | 2025 | 198 | 0.240 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2025 | 156 | 0.230 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 887 | 0.230 |
Why?
|
| Genome, Human | 2 | 2015 | 823 | 0.230 |
Why?
|
| Down-Regulation | 6 | 2020 | 524 | 0.230 |
Why?
|
| Alanine | 1 | 2025 | 83 | 0.230 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2025 | 50 | 0.230 |
Why?
|
| Amphiregulin | 1 | 2025 | 14 | 0.230 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2025 | 29 | 0.230 |
Why?
|
| DNA Methylation | 5 | 2025 | 697 | 0.230 |
Why?
|
| DNA-Binding Proteins | 5 | 2025 | 1234 | 0.220 |
Why?
|
| Mass Spectrometry | 3 | 2022 | 200 | 0.220 |
Why?
|
| Sensitivity and Specificity | 4 | 2023 | 1922 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2018 | 366 | 0.220 |
Why?
|
| Receptors, Glucocorticoid | 2 | 2017 | 144 | 0.220 |
Why?
|
| Pyrazoles | 2 | 2020 | 150 | 0.220 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2018 | 876 | 0.220 |
Why?
|
| Extracellular Vesicles | 2 | 2023 | 47 | 0.220 |
Why?
|
| Pseudogenes | 1 | 2004 | 35 | 0.220 |
Why?
|
| Inflammation | 1 | 2011 | 1050 | 0.220 |
Why?
|
| Menstrual Cycle | 1 | 2025 | 59 | 0.210 |
Why?
|
| Lymphatic Metastasis | 3 | 2005 | 504 | 0.210 |
Why?
|
| Forkhead Box Protein M1 | 1 | 2024 | 15 | 0.210 |
Why?
|
| Breast Neoplasms | 6 | 2008 | 3110 | 0.210 |
Why?
|
| Menopause | 1 | 2025 | 87 | 0.210 |
Why?
|
| Mice, Inbred C57BL | 4 | 2025 | 3435 | 0.210 |
Why?
|
| Cell Cycle | 3 | 2011 | 515 | 0.210 |
Why?
|
| Interleukin-10 | 1 | 2025 | 163 | 0.210 |
Why?
|
| Genital Neoplasms, Female | 2 | 2016 | 112 | 0.210 |
Why?
|
| Biomarkers | 3 | 2024 | 1910 | 0.210 |
Why?
|
| Adaptive Immunity | 1 | 2025 | 179 | 0.200 |
Why?
|
| Neovascularization, Pathologic | 2 | 2019 | 353 | 0.200 |
Why?
|
| Phosphorylation | 6 | 2015 | 1133 | 0.200 |
Why?
|
| Laminin | 3 | 2001 | 91 | 0.200 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2025 | 660 | 0.200 |
Why?
|
| Phosphoprotein Phosphatases | 3 | 2018 | 58 | 0.200 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2025 | 188 | 0.200 |
Why?
|
| Survival Rate | 6 | 2017 | 1948 | 0.200 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 1229 | 0.200 |
Why?
|
| Receptor Cross-Talk | 1 | 2023 | 33 | 0.200 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2024 | 83 | 0.190 |
Why?
|
| Circulating MicroRNA | 1 | 2023 | 14 | 0.190 |
Why?
|
| Molecular Sequence Data | 9 | 2013 | 2910 | 0.190 |
Why?
|
| B7-H1 Antigen | 1 | 2025 | 305 | 0.190 |
Why?
|
| Collagenases | 5 | 2001 | 42 | 0.190 |
Why?
|
| Phosphates | 1 | 2023 | 165 | 0.190 |
Why?
|
| Chromatography, Liquid | 2 | 2020 | 104 | 0.190 |
Why?
|
| Obstetric Labor, Premature | 1 | 2023 | 58 | 0.190 |
Why?
|
| Mice, Inbred BALB C | 4 | 2018 | 1101 | 0.190 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2020 | 108 | 0.180 |
Why?
|
| Gene Expression | 4 | 2016 | 1301 | 0.180 |
Why?
|
| rac1 GTP-Binding Protein | 4 | 2009 | 47 | 0.180 |
Why?
|
| Postmenopause | 1 | 2022 | 106 | 0.180 |
Why?
|
| Immunoenzyme Techniques | 2 | 2015 | 293 | 0.180 |
Why?
|
| Lymphocyte Activation | 1 | 2025 | 797 | 0.180 |
Why?
|
| Gene Knockdown Techniques | 2 | 2020 | 254 | 0.180 |
Why?
|
| Cell Growth Processes | 3 | 2015 | 83 | 0.180 |
Why?
|
| Lysophospholipids | 2 | 2019 | 67 | 0.180 |
Why?
|
| Anxiety | 2 | 2021 | 337 | 0.180 |
Why?
|
| Heterografts | 2 | 2020 | 116 | 0.180 |
Why?
|
| Genes, ras | 3 | 1997 | 97 | 0.170 |
Why?
|
| Fatty Acids | 1 | 2022 | 145 | 0.170 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2019 | 170 | 0.170 |
Why?
|
| Protein Binding | 6 | 2013 | 1534 | 0.170 |
Why?
|
| Leukocyte Elastase | 1 | 2021 | 7 | 0.170 |
Why?
|
| Hydrolases | 2 | 2018 | 29 | 0.170 |
Why?
|
| Premature Birth | 1 | 2023 | 129 | 0.170 |
Why?
|
| Platinum | 1 | 2021 | 67 | 0.170 |
Why?
|
| Mice, Knockout | 4 | 2025 | 2121 | 0.170 |
Why?
|
| Transcriptional Activation | 5 | 2002 | 290 | 0.170 |
Why?
|
| Cross-Sectional Studies | 4 | 2022 | 1847 | 0.160 |
Why?
|
| Plasminogen | 1 | 2001 | 46 | 0.160 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 3 | 1997 | 94 | 0.160 |
Why?
|
| Lipid Metabolism | 2 | 2020 | 214 | 0.160 |
Why?
|
| Germ-Line Mutation | 2 | 2021 | 381 | 0.160 |
Why?
|
| Melanoma | 2 | 2022 | 495 | 0.160 |
Why?
|
| BRCA2 Protein | 1 | 2021 | 173 | 0.160 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2020 | 25 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-jun | 4 | 2007 | 33 | 0.160 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2020 | 35 | 0.160 |
Why?
|
| B-Lymphocytes | 1 | 2025 | 701 | 0.160 |
Why?
|
| ras Proteins | 1 | 2001 | 132 | 0.160 |
Why?
|
| Protein Array Analysis | 1 | 2020 | 53 | 0.160 |
Why?
|
| Biphenyl Compounds | 1 | 2020 | 60 | 0.150 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2020 | 28 | 0.150 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2019 | 55 | 0.150 |
Why?
|
| Endometriosis | 2 | 2011 | 63 | 0.150 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 2 | 2001 | 166 | 0.150 |
Why?
|
| beta Catenin | 2 | 2014 | 265 | 0.150 |
Why?
|
| Base Sequence | 9 | 2013 | 2220 | 0.150 |
Why?
|
| Transplantation, Heterologous | 2 | 2012 | 371 | 0.150 |
Why?
|
| Amino Acid Sequence | 5 | 2018 | 2012 | 0.150 |
Why?
|
| Chromatin | 1 | 2022 | 440 | 0.150 |
Why?
|
| Cohort Studies | 6 | 2023 | 3056 | 0.150 |
Why?
|
| Enzymes | 1 | 2019 | 47 | 0.150 |
Why?
|
| Metabolomics | 1 | 2020 | 98 | 0.150 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 4 | 2010 | 66 | 0.150 |
Why?
|
| Immunotherapy | 3 | 2020 | 761 | 0.150 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2019 | 43 | 0.150 |
Why?
|
| Cell Death | 3 | 2021 | 253 | 0.150 |
Why?
|
| Transcription, Genetic | 6 | 2008 | 1117 | 0.140 |
Why?
|
| Hypertension | 1 | 2024 | 758 | 0.140 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2025 | 1261 | 0.140 |
Why?
|
| Obesity | 2 | 2018 | 1018 | 0.140 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 2 | 2009 | 11 | 0.140 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2021 | 291 | 0.140 |
Why?
|
| RNA | 1 | 2022 | 573 | 0.140 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2019 | 79 | 0.140 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2019 | 101 | 0.140 |
Why?
|
| RNA, Neoplasm | 1 | 2018 | 86 | 0.140 |
Why?
|
| Bevacizumab | 1 | 2019 | 256 | 0.140 |
Why?
|
| Primary Cell Culture | 2 | 2016 | 83 | 0.140 |
Why?
|
| Ultraviolet Rays | 1 | 1999 | 192 | 0.140 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 255 | 0.140 |
Why?
|
| Focal Adhesion Kinase 1 | 2 | 2024 | 30 | 0.140 |
Why?
|
| Cysteine Proteases | 1 | 2017 | 4 | 0.140 |
Why?
|
| Binding Sites | 8 | 2002 | 1133 | 0.130 |
Why?
|
| Cells | 1 | 2017 | 30 | 0.130 |
Why?
|
| Enzyme Assays | 1 | 2017 | 18 | 0.130 |
Why?
|
| Mice, Transgenic | 2 | 2011 | 1587 | 0.130 |
Why?
|
| Microfilament Proteins | 1 | 2019 | 209 | 0.130 |
Why?
|
| Plasminogen Activators | 1 | 1997 | 10 | 0.130 |
Why?
|
| Neoplasms, Experimental | 1 | 2018 | 263 | 0.130 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2018 | 123 | 0.130 |
Why?
|
| Receptors, Prolactin | 1 | 2017 | 10 | 0.130 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2008 | 122 | 0.130 |
Why?
|
| Energy Metabolism | 1 | 2019 | 299 | 0.130 |
Why?
|
| Leukocytes | 1 | 2018 | 210 | 0.130 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 224 | 0.130 |
Why?
|
| Embryo Implantation | 2 | 2023 | 24 | 0.130 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2018 | 319 | 0.130 |
Why?
|
| Genetic Testing | 1 | 2021 | 565 | 0.130 |
Why?
|
| Endothelial Cells | 4 | 2019 | 477 | 0.120 |
Why?
|
| Hyaluronan Receptors | 1 | 2016 | 40 | 0.120 |
Why?
|
| MAP Kinase Signaling System | 3 | 2018 | 200 | 0.120 |
Why?
|
| Patient-Centered Care | 1 | 2019 | 220 | 0.120 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2016 | 25 | 0.120 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1996 | 122 | 0.120 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2007 | 282 | 0.120 |
Why?
|
| fas Receptor | 2 | 2021 | 73 | 0.120 |
Why?
|
| Models, Statistical | 1 | 2019 | 585 | 0.120 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2016 | 68 | 0.120 |
Why?
|
| Genomic Instability | 1 | 2016 | 88 | 0.120 |
Why?
|
| Peritoneal Cavity | 1 | 2015 | 19 | 0.120 |
Why?
|
| Carbon | 1 | 2016 | 96 | 0.120 |
Why?
|
| Phylogeny | 2 | 2016 | 1266 | 0.120 |
Why?
|
| Protease Inhibitors | 3 | 2021 | 71 | 0.120 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 454 | 0.120 |
Why?
|
| Male | 12 | 2025 | 44564 | 0.120 |
Why?
|
| Organ Culture Techniques | 1 | 2015 | 121 | 0.120 |
Why?
|
| Exosomes | 1 | 2016 | 60 | 0.120 |
Why?
|
| Carrier Proteins | 1 | 2019 | 663 | 0.120 |
Why?
|
| Software | 1 | 2019 | 670 | 0.120 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2018 | 424 | 0.120 |
Why?
|
| Adenosine | 1 | 2018 | 275 | 0.110 |
Why?
|
| Risk Factors | 3 | 2021 | 5901 | 0.110 |
Why?
|
| Escin | 1 | 2015 | 1 | 0.110 |
Why?
|
| Prochlorperazine | 1 | 2015 | 1 | 0.110 |
Why?
|
| Tomatine | 1 | 2015 | 1 | 0.110 |
Why?
|
| Cantharidin | 1 | 2015 | 2 | 0.110 |
Why?
|
| Biguanides | 1 | 2015 | 5 | 0.110 |
Why?
|
| Benzophenanthridines | 1 | 2015 | 22 | 0.110 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2015 | 61 | 0.110 |
Why?
|
| Isoquinolines | 1 | 2015 | 57 | 0.110 |
Why?
|
| Survival Analysis | 4 | 2012 | 1524 | 0.110 |
Why?
|
| Fibroblast Growth Factor 1 | 1 | 2014 | 5 | 0.110 |
Why?
|
| Niclosamide | 1 | 2014 | 10 | 0.110 |
Why?
|
| Cell Line | 6 | 2009 | 2464 | 0.110 |
Why?
|
| Cell Cycle Proteins | 1 | 1997 | 409 | 0.110 |
Why?
|
| Uterine Neoplasms | 2 | 2010 | 277 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2010 | 75 | 0.110 |
Why?
|
| Integrins | 1 | 2014 | 79 | 0.110 |
Why?
|
| Hyperglycemia | 1 | 2015 | 181 | 0.100 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2014 | 86 | 0.100 |
Why?
|
| Chicago | 2 | 2024 | 1464 | 0.100 |
Why?
|
| Hyperlipidemias | 1 | 2014 | 91 | 0.100 |
Why?
|
| Macrophages, Peritoneal | 1 | 2014 | 25 | 0.100 |
Why?
|
| Wnt Proteins | 1 | 2014 | 127 | 0.100 |
Why?
|
| Arsenates | 1 | 2013 | 1 | 0.100 |
Why?
|
| Treatment Outcome | 6 | 2025 | 9103 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-raf | 4 | 1997 | 50 | 0.100 |
Why?
|
| Cross-Cultural Comparison | 1 | 1993 | 35 | 0.100 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2015 | 147 | 0.100 |
Why?
|
| ErbB Receptors | 2 | 2025 | 506 | 0.100 |
Why?
|
| Genes, Reporter | 3 | 2001 | 275 | 0.100 |
Why?
|
| Animals, Genetically Modified | 1 | 2013 | 186 | 0.100 |
Why?
|
| Young Adult | 3 | 2021 | 6930 | 0.100 |
Why?
|
| Mitochondria | 1 | 2016 | 612 | 0.090 |
Why?
|
| Neoplasm Transplantation | 2 | 2011 | 399 | 0.090 |
Why?
|
| Carcinosarcoma | 1 | 2012 | 29 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1995 | 688 | 0.090 |
Why?
|
| Estrogens | 2 | 2009 | 195 | 0.090 |
Why?
|
| Oxidative Stress | 1 | 2015 | 467 | 0.090 |
Why?
|
| Estrogen Antagonists | 1 | 2011 | 47 | 0.090 |
Why?
|
| Enzyme Induction | 3 | 2016 | 83 | 0.090 |
Why?
|
| Gonadoblastoma | 1 | 2011 | 1 | 0.090 |
Why?
|
| Dysgerminoma | 1 | 2011 | 7 | 0.090 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2012 | 152 | 0.090 |
Why?
|
| Tamoxifen | 1 | 2012 | 170 | 0.090 |
Why?
|
| SOX9 Transcription Factor | 1 | 2011 | 28 | 0.090 |
Why?
|
| Pregnancy | 5 | 2024 | 3147 | 0.090 |
Why?
|
| Polyethylene Glycols | 1 | 2013 | 373 | 0.090 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 1 | 2011 | 19 | 0.080 |
Why?
|
| Drug Interactions | 1 | 2011 | 239 | 0.080 |
Why?
|
| Ovarian Cysts | 1 | 2011 | 15 | 0.080 |
Why?
|
| Taxoids | 1 | 2011 | 126 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2013 | 1103 | 0.080 |
Why?
|
| HMGA2 Protein | 2 | 2007 | 15 | 0.080 |
Why?
|
| Sequence Deletion | 2 | 2009 | 209 | 0.080 |
Why?
|
| Mast Cells | 1 | 2011 | 96 | 0.080 |
Why?
|
| src-Family Kinases | 1 | 2010 | 70 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 394 | 0.080 |
Why?
|
| Forkhead Transcription Factors | 1 | 2011 | 174 | 0.080 |
Why?
|
| Intestinal Obstruction | 1 | 2011 | 93 | 0.080 |
Why?
|
| Testicular Neoplasms | 1 | 2011 | 120 | 0.080 |
Why?
|
| Adolescent | 2 | 2021 | 9607 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2007 | 80 | 0.080 |
Why?
|
| Mullerian Ducts | 1 | 2009 | 20 | 0.080 |
Why?
|
| Chronic Disease | 1 | 1993 | 960 | 0.080 |
Why?
|
| Pelvic Pain | 1 | 2011 | 86 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 4 | 1997 | 666 | 0.080 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2010 | 156 | 0.080 |
Why?
|
| Protein Isoforms | 2 | 2021 | 295 | 0.080 |
Why?
|
| Gonadotropins | 1 | 2009 | 33 | 0.080 |
Why?
|
| Child | 1 | 2021 | 7355 | 0.080 |
Why?
|
| Administration, Oral | 1 | 2011 | 657 | 0.080 |
Why?
|
| Ascites | 2 | 2023 | 54 | 0.080 |
Why?
|
| Ovarian Diseases | 1 | 2009 | 28 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2011 | 603 | 0.080 |
Why?
|
| Hysterectomy | 1 | 2011 | 167 | 0.070 |
Why?
|
| Integrases | 1 | 2009 | 66 | 0.070 |
Why?
|
| Trophoblasts | 1 | 2009 | 35 | 0.070 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2009 | 57 | 0.070 |
Why?
|
| Intestine, Small | 1 | 2011 | 310 | 0.070 |
Why?
|
| Precision Medicine | 1 | 2013 | 456 | 0.070 |
Why?
|
| RNA-Binding Proteins | 1 | 2011 | 306 | 0.070 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2008 | 13 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2021 | 2465 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1995 | 1077 | 0.070 |
Why?
|
| Cattle | 1 | 2009 | 397 | 0.070 |
Why?
|
| Liver | 2 | 2005 | 1210 | 0.070 |
Why?
|
| Staining and Labeling | 1 | 2009 | 158 | 0.070 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2009 | 178 | 0.070 |
Why?
|
| Abdominal Cavity | 1 | 2008 | 17 | 0.070 |
Why?
|
| Receptor, PAR-1 | 1 | 2007 | 1 | 0.070 |
Why?
|
| Colorectal Neoplasms | 2 | 2007 | 1053 | 0.070 |
Why?
|
| Procollagen-Proline Dioxygenase | 1 | 2007 | 10 | 0.070 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2007 | 28 | 0.070 |
Why?
|
| CA-125 Antigen | 1 | 2007 | 21 | 0.070 |
Why?
|
| Models, Animal | 1 | 2009 | 282 | 0.070 |
Why?
|
| Vimentin | 1 | 2007 | 47 | 0.070 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 3 | 1996 | 26 | 0.070 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2007 | 10 | 0.070 |
Why?
|
| Thyroid Neoplasms | 2 | 2005 | 442 | 0.060 |
Why?
|
| Sp1 Transcription Factor | 2 | 2005 | 24 | 0.060 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2006 | 12 | 0.060 |
Why?
|
| Time Factors | 5 | 2018 | 5412 | 0.060 |
Why?
|
| Osteosarcoma | 1 | 2007 | 158 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 3476 | 0.060 |
Why?
|
| Phenotype | 4 | 2019 | 2544 | 0.060 |
Why?
|
| DNA | 3 | 2004 | 1265 | 0.060 |
Why?
|
| Mice, SCID | 2 | 2018 | 271 | 0.060 |
Why?
|
| Antibodies | 1 | 2008 | 348 | 0.060 |
Why?
|
| Genes, jun | 2 | 1996 | 18 | 0.060 |
Why?
|
| Hematologic Diseases | 1 | 2006 | 77 | 0.060 |
Why?
|
| Health Status Disparities | 1 | 2008 | 219 | 0.060 |
Why?
|
| Tissue Fixation | 2 | 2020 | 39 | 0.060 |
Why?
|
| Longitudinal Studies | 3 | 2022 | 1161 | 0.060 |
Why?
|
| Paraffin Embedding | 2 | 2020 | 77 | 0.060 |
Why?
|
| Gene Expression Regulation | 4 | 2002 | 1985 | 0.060 |
Why?
|
| Breast | 1 | 2007 | 294 | 0.060 |
Why?
|
| Mutagenesis | 2 | 2015 | 192 | 0.060 |
Why?
|
| Fibrocystic Breast Disease | 1 | 2005 | 12 | 0.060 |
Why?
|
| Bone Neoplasms | 1 | 2007 | 313 | 0.060 |
Why?
|
| Cell Division | 5 | 2012 | 693 | 0.060 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2025 | 13 | 0.060 |
Why?
|
| Chemokine CXCL13 | 1 | 2025 | 17 | 0.060 |
Why?
|
| Brain Stem Neoplasms | 1 | 2005 | 21 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2015 | 691 | 0.050 |
Why?
|
| Sarcoma | 1 | 2006 | 222 | 0.050 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2024 | 36 | 0.050 |
Why?
|
| Hyperplasia | 1 | 2005 | 147 | 0.050 |
Why?
|
| Blotting, Southern | 1 | 2004 | 110 | 0.050 |
Why?
|
| Phagocytosis | 1 | 2025 | 111 | 0.050 |
Why?
|
| Repressor Proteins | 1 | 2008 | 443 | 0.050 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2004 | 159 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2007 | 664 | 0.050 |
Why?
|
| Postnatal Care | 1 | 2024 | 30 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2019 | 398 | 0.050 |
Why?
|
| Myeloid Cells | 1 | 2025 | 119 | 0.050 |
Why?
|
| Gestational Trophoblastic Disease | 1 | 2004 | 2 | 0.050 |
Why?
|
| Tissue Array Analysis | 2 | 2017 | 134 | 0.050 |
Why?
|
| Dactinomycin | 1 | 2004 | 32 | 0.050 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2006 | 188 | 0.050 |
Why?
|
| Bone Marrow | 1 | 2006 | 409 | 0.050 |
Why?
|
| Blood Pressure Determination | 1 | 2024 | 69 | 0.050 |
Why?
|
| Hypoxia | 1 | 2009 | 675 | 0.050 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2004 | 404 | 0.050 |
Why?
|
| Phthalazines | 1 | 2024 | 53 | 0.050 |
Why?
|
| Receptors, Progesterone | 1 | 2005 | 196 | 0.050 |
Why?
|
| Sequence Alignment | 1 | 2004 | 352 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2004 | 111 | 0.050 |
Why?
|
| Cloning, Molecular | 1 | 2004 | 587 | 0.050 |
Why?
|
| Methotrexate | 1 | 2004 | 225 | 0.050 |
Why?
|
| Postpartum Period | 1 | 2024 | 159 | 0.050 |
Why?
|
| Blotting, Northern | 2 | 2001 | 244 | 0.050 |
Why?
|
| HEK293 Cells | 2 | 2019 | 696 | 0.050 |
Why?
|
| Ascitic Fluid | 1 | 2023 | 37 | 0.050 |
Why?
|
| Lymph Node Excision | 1 | 2005 | 233 | 0.050 |
Why?
|
| RNA Splicing | 1 | 2004 | 157 | 0.050 |
Why?
|
| Liver Neoplasms | 2 | 2010 | 776 | 0.050 |
Why?
|
| Proteins | 3 | 2004 | 803 | 0.050 |
Why?
|
| Receptors, Estrogen | 1 | 2005 | 413 | 0.050 |
Why?
|
| Liquid Biopsy | 1 | 2023 | 48 | 0.050 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2006 | 318 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-fos | 2 | 2007 | 66 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2016 | 1914 | 0.050 |
Why?
|
| Follow-Up Studies | 5 | 2012 | 3832 | 0.050 |
Why?
|
| Piperazines | 1 | 2024 | 284 | 0.050 |
Why?
|
| Laser Capture Microdissection | 1 | 2022 | 20 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2024 | 4562 | 0.050 |
Why?
|
| Immune Tolerance | 1 | 2025 | 375 | 0.050 |
Why?
|
| Prenatal Care | 1 | 2023 | 80 | 0.050 |
Why?
|
| Delivery, Obstetric | 1 | 2023 | 121 | 0.050 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2003 | 110 | 0.050 |
Why?
|
| Endothelium, Vascular | 2 | 2002 | 436 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2005 | 917 | 0.050 |
Why?
|
| Recombinant Proteins | 3 | 2002 | 988 | 0.040 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2025 | 337 | 0.040 |
Why?
|
| Gastrins | 1 | 2001 | 15 | 0.040 |
Why?
|
| Transcription Factor AP-2 | 3 | 2007 | 14 | 0.040 |
Why?
|
| Morbidity | 1 | 2022 | 162 | 0.040 |
Why?
|
| Eosinophil Cationic Protein | 1 | 2021 | 3 | 0.040 |
Why?
|
| Secretory Leukocyte Peptidase Inhibitor | 1 | 2021 | 4 | 0.040 |
Why?
|
| Nuclear Proteins | 3 | 2002 | 740 | 0.040 |
Why?
|
| Receptors, Vitronectin | 1 | 2001 | 5 | 0.040 |
Why?
|
| Pancreatic Elastase | 1 | 2021 | 15 | 0.040 |
Why?
|
| Telemedicine | 1 | 2024 | 225 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2005 | 548 | 0.040 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 2001 | 18 | 0.040 |
Why?
|
| Homologous Recombination | 1 | 2021 | 57 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2025 | 463 | 0.040 |
Why?
|
| Allosteric Regulation | 1 | 2021 | 68 | 0.040 |
Why?
|
| Endopeptidases | 1 | 2001 | 116 | 0.040 |
Why?
|
| Chemokine CCL2 | 1 | 2001 | 45 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2025 | 1729 | 0.040 |
Why?
|
| Reperfusion | 1 | 2001 | 31 | 0.040 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2001 | 251 | 0.040 |
Why?
|
| Cryopreservation | 1 | 2001 | 71 | 0.040 |
Why?
|
| Luciferases | 1 | 2001 | 129 | 0.040 |
Why?
|
| Arteriosclerosis | 1 | 2001 | 106 | 0.040 |
Why?
|
| Proteolysis | 1 | 2021 | 123 | 0.040 |
Why?
|
| Protein Domains | 1 | 2021 | 161 | 0.040 |
Why?
|
| MAP Kinase Kinase 1 | 2 | 1997 | 38 | 0.040 |
Why?
|
| Membrane Transport Proteins | 1 | 2001 | 169 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2001 | 150 | 0.040 |
Why?
|
| Succinate-CoA Ligases | 1 | 2019 | 2 | 0.040 |
Why?
|
| Prolyl Hydroxylases | 1 | 2019 | 4 | 0.040 |
Why?
|
| Flavonoids | 2 | 1997 | 85 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2002 | 439 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2002 | 408 | 0.040 |
Why?
|
| Immunoprecipitation | 1 | 2019 | 136 | 0.040 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2020 | 50 | 0.040 |
Why?
|
| Swine | 1 | 2021 | 588 | 0.040 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2019 | 62 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2011 | 2563 | 0.040 |
Why?
|
| S-Adenosylhomocysteine | 1 | 2019 | 11 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2001 | 476 | 0.040 |
Why?
|
| S-Adenosylmethionine | 1 | 2019 | 28 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2001 | 444 | 0.040 |
Why?
|
| Niacinamide | 1 | 2019 | 101 | 0.040 |
Why?
|
| Placenta | 1 | 2000 | 189 | 0.040 |
Why?
|
| Protein Precursors | 1 | 1999 | 135 | 0.040 |
Why?
|
| Heparin | 1 | 2019 | 181 | 0.040 |
Why?
|
| Societies, Scientific | 1 | 2019 | 41 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2018 | 13 | 0.040 |
Why?
|
| Sphingosine | 1 | 2019 | 73 | 0.040 |
Why?
|
| Small Molecule Libraries | 1 | 2019 | 69 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2022 | 1546 | 0.030 |
Why?
|
| HeLa Cells | 2 | 2011 | 517 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2019 | 124 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2018 | 216 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 2 | 2016 | 347 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2018 | 215 | 0.030 |
Why?
|
| Tretinoin | 1 | 1998 | 129 | 0.030 |
Why?
|
| Genetic Engineering | 1 | 2018 | 100 | 0.030 |
Why?
|
| Pre-Eclampsia | 1 | 2000 | 261 | 0.030 |
Why?
|
| Dual Specificity Phosphatase 1 | 1 | 1997 | 17 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2019 | 179 | 0.030 |
Why?
|
| Tissue Scaffolds | 1 | 2018 | 128 | 0.030 |
Why?
|
| Protein Phosphatase 1 | 1 | 1997 | 31 | 0.030 |
Why?
|
| Vanadates | 1 | 1997 | 32 | 0.030 |
Why?
|
| Oligonucleotides | 1 | 2017 | 92 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 1997 | 46 | 0.030 |
Why?
|
| Placental Lactogen | 1 | 2017 | 12 | 0.030 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2017 | 35 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2014 | 367 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 1999 | 376 | 0.030 |
Why?
|
| Prolactin | 1 | 2017 | 89 | 0.030 |
Why?
|
| Methyltransferases | 1 | 2018 | 213 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2023 | 2479 | 0.030 |
Why?
|
| HLA Antigens | 1 | 2018 | 228 | 0.030 |
Why?
|
| Matrix Metalloproteinases | 1 | 2016 | 30 | 0.030 |
Why?
|
| Carcinoma, Papillary | 1 | 1998 | 159 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2017 | 93 | 0.030 |
Why?
|
| Oncogene Proteins v-fos | 1 | 1996 | 3 | 0.030 |
Why?
|
| Cell Shape | 1 | 2016 | 50 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 3 | 2001 | 122 | 0.030 |
Why?
|
| Datasets as Topic | 1 | 2016 | 81 | 0.030 |
Why?
|
| Immediate-Early Proteins | 1 | 1997 | 161 | 0.030 |
Why?
|
| Endocytosis | 1 | 2017 | 184 | 0.030 |
Why?
|
| Metabolome | 1 | 2016 | 62 | 0.030 |
Why?
|
| Gadolinium DTPA | 1 | 2017 | 233 | 0.030 |
Why?
|
| Phenformin | 1 | 2015 | 6 | 0.030 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2015 | 14 | 0.030 |
Why?
|
| Substrate Specificity | 1 | 2016 | 363 | 0.030 |
Why?
|
| Aspirin | 1 | 2017 | 167 | 0.030 |
Why?
|
| Restriction Mapping | 1 | 1995 | 120 | 0.030 |
Why?
|
| Genes, Neurofibromatosis 1 | 1 | 2015 | 2 | 0.030 |
Why?
|
| Cell Differentiation | 3 | 2012 | 1621 | 0.030 |
Why?
|
| Genes, erbB-2 | 1 | 1995 | 25 | 0.030 |
Why?
|
| RNAi Therapeutics | 1 | 2015 | 2 | 0.030 |
Why?
|
| Cyclin E | 1 | 2015 | 28 | 0.030 |
Why?
|
| Codon | 1 | 1995 | 116 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2017 | 512 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2018 | 277 | 0.030 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 3 | 2001 | 98 | 0.030 |
Why?
|
| Lactic Acid | 1 | 2015 | 104 | 0.030 |
Why?
|
| Cisplatin | 2 | 2008 | 568 | 0.030 |
Why?
|
| Cell Nucleus | 2 | 2011 | 603 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2015 | 120 | 0.030 |
Why?
|
| Trypsin | 1 | 1995 | 94 | 0.030 |
Why?
|
| Protein Kinases | 1 | 1996 | 210 | 0.030 |
Why?
|
| Mifepristone | 1 | 2015 | 51 | 0.030 |
Why?
|
| Retinoblastoma Protein | 1 | 2015 | 68 | 0.030 |
Why?
|
| Epitopes | 1 | 1995 | 254 | 0.030 |
Why?
|
| Oncogene Proteins | 1 | 2015 | 65 | 0.030 |
Why?
|
| Molecular Weight | 1 | 1995 | 292 | 0.030 |
Why?
|
| Random Allocation | 1 | 2015 | 307 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2015 | 123 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 2 | 2005 | 74 | 0.030 |
Why?
|
| Lovastatin | 1 | 2014 | 28 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 151 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2015 | 156 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2015 | 187 | 0.030 |
Why?
|
| Solubility | 1 | 1995 | 187 | 0.030 |
Why?
|
| Genes, BRCA2 | 1 | 2015 | 162 | 0.030 |
Why?
|
| Genes, BRCA1 | 1 | 2015 | 191 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2015 | 213 | 0.030 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2016 | 297 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2014 | 256 | 0.030 |
Why?
|
| Liver Transplantation | 1 | 2001 | 1194 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2014 | 103 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 543 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2014 | 139 | 0.020 |
Why?
|
| Hungary | 1 | 1993 | 3 | 0.020 |
Why?
|
| Quality of Life | 1 | 2022 | 1780 | 0.020 |
Why?
|
| Multiphasic Screening | 1 | 1993 | 1 | 0.020 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2012 | 16 | 0.020 |
Why?
|
| Chemokine CXCL12 | 1 | 2012 | 38 | 0.020 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2012 | 45 | 0.020 |
Why?
|
| Paracrine Communication | 1 | 2012 | 32 | 0.020 |
Why?
|
| Vagina | 1 | 1993 | 177 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2012 | 103 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2014 | 712 | 0.020 |
Why?
|
| Umbilical Veins | 2 | 2002 | 45 | 0.020 |
Why?
|
| DNA Primers | 2 | 2004 | 531 | 0.020 |
Why?
|
| Health Planning Guidelines | 1 | 2011 | 23 | 0.020 |
Why?
|
| CHO Cells | 2 | 2002 | 187 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 1993 | 188 | 0.020 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1995 | 378 | 0.020 |
Why?
|
| Forkhead Box Protein L2 | 1 | 2011 | 3 | 0.020 |
Why?
|
| Cricetinae | 2 | 2002 | 532 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2012 | 276 | 0.020 |
Why?
|
| Cytoplasm | 2 | 2002 | 278 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2011 | 309 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2012 | 215 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2010 | 96 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2011 | 91 | 0.020 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2011 | 72 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2010 | 21 | 0.020 |
Why?
|
| Fas Ligand Protein | 1 | 2010 | 47 | 0.020 |
Why?
|
| Lung Neoplasms | 2 | 2005 | 2365 | 0.020 |
Why?
|
| RNA Interference | 1 | 2011 | 379 | 0.020 |
Why?
|
| Gelatinases | 2 | 2001 | 10 | 0.020 |
Why?
|
| Metalloendopeptidases | 2 | 2001 | 44 | 0.020 |
Why?
|
| Surface Properties | 1 | 2009 | 126 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2011 | 321 | 0.020 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2009 | 31 | 0.020 |
Why?
|
| Hepatocytes | 1 | 2010 | 129 | 0.020 |
Why?
|
| Snail Family Transcription Factors | 1 | 2009 | 48 | 0.020 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2009 | 132 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2007 | 1713 | 0.020 |
Why?
|
| Formaldehyde | 1 | 2009 | 51 | 0.020 |
Why?
|
| Enzyme Activation | 2 | 2001 | 674 | 0.020 |
Why?
|
| Incidence | 1 | 1993 | 1702 | 0.020 |
Why?
|
| Infusions, Parenteral | 1 | 2008 | 46 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 1995 | 1173 | 0.020 |
Why?
|
| Zinc Finger E-box Binding Homeobox 2 | 1 | 2008 | 2 | 0.020 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2008 | 5 | 0.020 |
Why?
|
| Stem Cells | 1 | 2011 | 387 | 0.020 |
Why?
|
| Aging | 1 | 1993 | 727 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2008 | 162 | 0.020 |
Why?
|
| Protein Transport | 1 | 2009 | 438 | 0.020 |
Why?
|
| Suppression, Genetic | 1 | 2007 | 30 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2008 | 401 | 0.020 |
Why?
|
| 3T3 Cells | 2 | 1999 | 94 | 0.020 |
Why?
|
| Genes, Dominant | 1 | 2007 | 111 | 0.020 |
Why?
|
| Chick Embryo | 1 | 2007 | 222 | 0.020 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2006 | 27 | 0.020 |
Why?
|
| Reference Values | 2 | 2001 | 608 | 0.020 |
Why?
|
| Femur Head | 1 | 2006 | 8 | 0.020 |
Why?
|
| Leukopenia | 1 | 2006 | 64 | 0.020 |
Why?
|
| Glioma | 1 | 2009 | 301 | 0.020 |
Why?
|
| Lumbosacral Region | 1 | 2006 | 57 | 0.010 |
Why?
|
| Ilium | 1 | 2006 | 30 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 2007 | 259 | 0.010 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2006 | 97 | 0.010 |
Why?
|
| Neutropenia | 1 | 2006 | 209 | 0.010 |
Why?
|
| Sacrum | 1 | 2006 | 83 | 0.010 |
Why?
|
| Neoplasms, Bone Tissue | 1 | 2005 | 2 | 0.010 |
Why?
|
| Calcitonin | 1 | 2005 | 40 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 2006 | 189 | 0.010 |
Why?
|
| T-Lymphoma Invasion and Metastasis-inducing Protein 1 | 1 | 2004 | 7 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2006 | 472 | 0.010 |
Why?
|
| Anemia | 1 | 2006 | 134 | 0.010 |
Why?
|
| Mediastinum | 1 | 2005 | 43 | 0.010 |
Why?
|
| Rats | 2 | 2001 | 4072 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2009 | 1932 | 0.010 |
Why?
|
| Cervix Uteri | 1 | 2005 | 73 | 0.010 |
Why?
|
| NIH 3T3 Cells | 1 | 2004 | 111 | 0.010 |
Why?
|
| Angiography | 1 | 2005 | 192 | 0.010 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2004 | 75 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2006 | 884 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2011 | 3829 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2004 | 282 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2004 | 436 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2004 | 829 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2006 | 1723 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2002 | 141 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2005 | 2585 | 0.010 |
Why?
|
| Vesicular Biogenic Amine Transport Proteins | 1 | 2001 | 2 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2002 | 309 | 0.010 |
Why?
|
| Enterochromaffin Cells | 1 | 2001 | 2 | 0.010 |
Why?
|
| Vesicular Monoamine Transport Proteins | 1 | 2001 | 3 | 0.010 |
Why?
|
| Chromogranin A | 1 | 2001 | 8 | 0.010 |
Why?
|
| Histidine Decarboxylase | 1 | 2001 | 6 | 0.010 |
Why?
|
| Chromogranins | 1 | 2001 | 11 | 0.010 |
Why?
|
| Enzyme Precursors | 1 | 2001 | 20 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 2001 | 57 | 0.010 |
Why?
|
| PC12 Cells | 1 | 2001 | 111 | 0.010 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2001 | 46 | 0.010 |
Why?
|
| Integrin beta3 | 1 | 2001 | 31 | 0.010 |
Why?
|
| Platelet Activation | 1 | 2001 | 18 | 0.010 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2001 | 39 | 0.010 |
Why?
|
| Rats, Inbred Lew | 1 | 2001 | 214 | 0.010 |
Why?
|
| HELLP Syndrome | 1 | 2000 | 8 | 0.010 |
Why?
|
| Guanosine Diphosphate | 1 | 2000 | 18 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2001 | 228 | 0.010 |
Why?
|
| Guanosine Triphosphate | 1 | 2000 | 36 | 0.010 |
Why?
|
| Translocation, Genetic | 1 | 2001 | 248 | 0.010 |
Why?
|
| Breast Diseases | 1 | 2000 | 99 | 0.010 |
Why?
|
| Monocytes | 1 | 2001 | 215 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2001 | 729 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2001 | 988 | 0.010 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 1998 | 18 | 0.010 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 1998 | 17 | 0.010 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 1998 | 24 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2001 | 353 | 0.010 |
Why?
|
| Chemotaxis | 1 | 1998 | 74 | 0.010 |
Why?
|
| Thyroglobulin | 1 | 1998 | 59 | 0.010 |
Why?
|
| Drug Combinations | 1 | 1998 | 200 | 0.010 |
Why?
|
| Proteoglycans | 1 | 1998 | 122 | 0.010 |
Why?
|
| DNA Footprinting | 1 | 1997 | 17 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1998 | 266 | 0.010 |
Why?
|
| Collagen | 1 | 1998 | 304 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1996 | 125 | 0.010 |
Why?
|
| Recurrence | 1 | 1999 | 1191 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 1998 | 452 | 0.010 |
Why?
|
| Keratin-10 | 1 | 1993 | 1 | 0.010 |
Why?
|
| Immunocompetence | 1 | 1993 | 24 | 0.010 |
Why?
|
| Blood Chemical Analysis | 1 | 1993 | 40 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2000 | 2484 | 0.010 |
Why?
|
| Blood Pressure | 1 | 1993 | 896 | 0.000 |
Why?
|